MedTrace Logo

Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia

NCT07354191 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-21

No results posted yet for this study

Summary

Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.

Conditions

Interventions

DIAGNOSTIC_TEST

direct antiglobulin test (DAT)

Serum sample

DIAGNOSTIC_TEST

Indirect antiglobulin test (IAT)

Serum sample

Sponsors & Collaborators

  • New Valley University

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2025-11-05
Completion
2025-11-06

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354191 on ClinicalTrials.gov